A key FDA advisory committee rejected the use of a psychedelic drug to help patients struggling with PTSD, questioning its safety and effectiveness. The FDA must now decide whether it will follow suit and reject the use of what's known as MDMA. Some patients and researchers had long hoped the government would approve it. Science correspondent Miles O'Brien reports. PBS News is supported by - https://www.pbs.org/newshour/about/funders